A. Barry Rand, Sue Rataj

Sep 16, 2015

Agilent Technologies announced changes to its board with the resignation of A. Barry Rand and the election of Sue Rataj. 

Rand's resignation is effective Oct. 31. He has been a board member since 2000 and serves on the compensation committee and nominating/corporate governance committee. His departure is not the result of any disagreement with the firm regarding its operations, policies, or practices, Agilent said.

Meanwhile, Rataj joined the board effective Sept. 15. She was chief executive of BP's global petrochemicals business before retiring in April 2011. Before that, she was a group president at BP. Following her retirement from the firm, Rataj joined the board of Cabot and the supervisory board of Bayer.

More Like This

Sep 20, 2017

Olivier Elemento

Olivier Elemento has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, succeeding Mark Rubin, the institute's founding director. Elemento was most recently director of the institute's computational biology group. He is also the associate director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine and co-leader of the Genetics, Epigenetics, and Systems Biology program in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. He holds a bachelor's degree in mechanical engineering from University Paul Sabatier, a master's degree in mechanical engineering from INSA Toulouse, and a doctorate in computational biology from the University of Montpellier/CNRS.

Sep 20, 2017

Sir Andrew Witty

Synthego announced that it has appointed Sir Andrew Witty to its advisory board. Witty is the former CEO of GlaxoSmithKline, where he also served on the board of directors from 2008 to April 2017. He currently serves as a director at UnitedHealth Group and chancellor of the University of Nottingham. Witty has more than 30 years of biopharma experience ranging from product management and business development, to strategic partnerships, including significant international experience serving in a number of senior roles in Europe and Asia while at GSK.

Sep 19, 2017

Michael Korn

Michael Korn has been appointed the chief medical officer of Caris Life Sciences, where he will guide the firm's research efforts and clinical strategies for the Adapt Biotargeting System and Caris Molecular Intelligence tumor profiling. Korn is a professor of medicine in the division of hematology/concology at the University of California, San Francisco, and he replaces John Marshal, who was CMO for Caris on a part-time basis. Marshall will continue as chairman of the Precision Oncology Alliance, which is powered by Caris.

Sep 18, 2017

Andy Wilson

PerkinElmer announced that Senior Vice President and CFO Andy Wilson has decided to retire. In order to allow for time to identify a successor for the CFO position and ensure a smooth transition, Wilson will retire in August 2018, the company said. He has held the position since joining PerkinElmer in 2009. The firm has hired an executive recruiting firm to assist in an external search to fill the CFO position.

Sep 14, 2017

Rob Brainin

WuXi Nextcode has appointed Rob Brainin as its executive vice president and chief operating officer. Brainin joins the company from Illumina, where he was vice president and general manager of life sciences and applied genomics for more than 15 years. Brainin also led business units at Invitrogen, Life Technologies, and Thermo Fisher Scientific. Prior to that, he held leadership positions at Gateway Computing.

Sep 13, 2017

Felice Schnoll-Sussman

Felice Schnoll-Sussman has been elected a director at Interpace Diagnostics, where she will serve on the firm's audit committee. She will be a Class II director and her term expires in 2018. Schnoll-Sussman is an associate professor of clinical medicine at Weill Cornell Medical College, where she is the director of the Jay Monahan Center for Gastrointestinal Health. She also is associate attending physician in gastroenterology at New York Presbyterian Hospital. 

Sep 12, 2017

Tim Sullivan

Tim Sullivan is stepping down as CEO of Ancestry, effective October 1. He will remain chairman of the company's board of directors. Howard Hochhauser, Ancestry's CFO and COO, will serve as interim CEO while the company searches for a permanent chief executive.

Sep 12, 2017

Gerald Krueger

DermTech has appointed Gerald Krueger to its scientific advisory board. Krueger is a professor of dermatology and Edna Benning Presidential Endowed Chair at the University of Utah. He received his medical degree from Loma Linda University and completed his residency in dermatology at the University of Colorado. Krueger is also the recipient of the Taub International Award for Psoriasis Research and a National Psoriasis Foundation Lifetime Achievement Award. DermTech noted that Krueger will help guide the company's efforts to develop non-invasive gene expression tests for inflammatory skin conditions.

Sep 11, 2017

James Ostell

Molecular biologist and former software developer James Ostell has been named director of the US National Center for Biotechnology Information, within the National Library of Medicine. This represents a promotion for Ostell, who previously headed NCBI's Information Engineering Branch. He has been with NCBI since its inception in 1988.

Sep 08, 2017

Jamie Platt

Jamie Platt has joined Inivata as chief operations officer. She will be based at Inivata's Research Triangle Park, North Carolina facility. Platt joins Inivata from Quest Diagnostics, where she helped lead that company's early advanced sequencing strategy and product portfolio. She holds a PhD in molecular and cellular biology from Oregon State University and completed her postdoc in population genetics at the University of California, Berkeley.

Sep 07, 2017

David Sanchez, Niraj Nagrani, Leila Pourashemi

Ancestry has added David Sanchez, Niraj Nagrani, and Leila Pourhashemi to its product and technology team. Sanchez joins as vice president, DNA product. He is formerly the head of product for Alexa at Amazon Lab126. Nagrani will help lead Ancestry's efforts to strengthen its web, mobile, cloud, and data technology platform and to complete its successful migration to the Amazon Web Services cloud. He was previously senior vice president of platform at American Express. Pourhashemi will be Ancestry's vice president of business operations, and joins the company from Intui.

Sep 07, 2017

Jos Lunenberg

Jos Lunenberg has been appointed as CEO of Enpicom, a Netherlands-based bioinformatics firm developing software to support immunotherapy development, patient stratification, and treatment monitoring. Lunenberg previously founded health tehcnology firm VitaMagna, and was co-owner and chief business officer for Genalice. He has also served as a member of the executive management team of Cerus Europe, Cryo-Save, and Organon.

Sep 06, 2017

Michael Brawer

MDxHealth has appointed Michael Brawer as chief medical officer. Brawer is a urologist and former professor of urology and pathology. He most recently served as vice president of medical affairs for urology at Myriad Genetics, where he led all clinical aspects of development, education, and commercialization of the firm's prognostic prostate cancer assay. Previously, Brawer held senior leadership positions at GTx, Tokai Pharmaceuticals, and Threshold Pharmaceuticals. HE was also a practicing urologist and the director of the Northwest Prostate Institute for almost a decade, and held teaching positions in pathology and urology at the University of Washington and University of Arizona.

Sep 05, 2017

Philip Smalley

Philip Smalley has joined Wamberg Genomic Advisors as its chief medical director. An internal medicine specialist, Smalley will be responsible for WGA's medical research. Prior to joining the firm, he served as senior vice president and global chief medical officer for RGA International. He also served as managing director of the Longer Life Foundation, an RGA/Washington University in St. Louis partnership that funds research on the determinants of longevity and promoting quality and quantity of life. Smalley received his medical degree from the University of Toronto, after which he practiced and taught medicine at a University of Toronto-affiliated teaching hospital. He is a fellow of the Royal College of Physicians and Surgeons of Canada and past president of the Canadian Life Insurance Medical Officers Association.

Sep 05, 2017

Michael Vicari

OncoCyte has appointed Michael Vicari to a newly created position of vice president of sales, in which he will report directly to president and CEO William Annett. In his new role, Vicari will be responsible for the development and successful implementation of domestic and international sales strategies for OncoCyte, with an initial focus on the expected fourth quarter US launch of the firm's liquid biopsy lung cancer test DetermaVu.

Vicari comes with 35 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products, OncoCyte said. He previously worked with Eurofins Scientific as VP of sales & marketing for the company's clinical diagnostics business. Prior to Eurofins, he was VP of sales for Sequenom, for Monogram Biosciences, and served in senior commercial leadership roles at Genentech, Corixa Oncology, and MedImmune.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.